Roberts joins Assembly with over 12 years of experience at global network agencies, including Dentsu and GroupM. He most recently served as the Head of Paid Search at Wavemaker, where he redefined product and accelerated search maturity. Collaborating closely with Google, Roberts spearheaded the adoption of Performance Max and other pioneering AI-driven ad formats. Roberts has garnered several impressive accolades during his tenure, such as the Drum Search Awards “Rising Star” in 2015. He was also named one of Google’s Top 20 Search Specialists and one of the most influential people in the UK for Paid Search by Adthena.

“I am excited to join Assembly as the Head of Search & E-commerce across Europe at a pivotal moment when search is being rapidly transformed by advancements in artificial intelligence. I am eager to use my expertise to help shape the future of search and e-commerce,” said Roberts. “I’m excited to create an agile, forward-thinking, data-driven product proposition for the agency and our clients; powered by a perfect blend of human talent and AI to maximize performance. I want to define a new standard in the industry, and Assembly is the perfect place for me to do that.”

Assembly Europe CEO Matt Adams adds, “Dan has a unique approach to driving performance and is dedicated to blending human talent with responsible AI that will make a real difference for our clients. As we continue evolving as an agency and adapting to the ever-changing digital landscape, Dan will play a pivotal role in our success.”

Roberts’ appointment is effective October 2023.

ABOUT ASSEMBLY
Assembly is the modern global omnichannel media agency, bringing data, talent, and technology together to find the change that fuels growth for the best brands on the planet. Our approach connects big, bold brand stories with integrated, global media capabilities that deliver performance and drive large-scale business growth. Our work is powered by our proprietary, in-house technology solution, STAGE, and led by our global talent base of over 1,600 people around the world. We’re purpose-driven at our core and pioneers in social and environmental impact in the agency world. Assembly is a proud member of Stagwell, the challenger network built to transform marketing. For more information, visit assemblyglobal.com. 

Media Relations Contact:
Jess Santini, VP, Global Marketing
jess.santini@assemblyglobal.com    

“For nearly 90 years, reinvention has been at our core, but we’ve never experienced a year quite like this,” said Christine Fruechte, chief executive officer, Colle McVoy. “This award recognizes our unique model, distinctive approach to creativity, business results and, ultimately, our award-winning culture focused on our people and clients.”

Colle McVoy is the agency of record for this new era of brand building. It transformed its operational model, reset its capabilities, became a Certified B Corporation and created powerful, connected ideas. These changes have helped it attract blue-chip clients like HARIBO, La-Z-Boy and CRAFTSMAN, leading to significant growth, along with unprecedented employee and client NPS ratings.

“Our unique mix of capabilities means we can connect the dots across a brand’s entire ecosystem,” said Jessica Henrichs, president, Colle McVoy. “We have felt the momentum, and we understand the advantage to us and to our clients of being a perfectly midsized, Midwestern agency built to solve problems in this complex time.”

Earning Adweek’s Midsize Agency of the Year award was also due in part to Colle McVoy’s ability to creatively reach audiences in diverse and distinct ways. In addition to the creative, strategy, brand experience and creative technology practices, the agency has doubled down on its key points of difference by significantly growing its media, PR, data science and design practices, allowing teams to get to outsized, culturally relevant ideas faster.

“We don’t have a creative ‘signature’ because the work isn’t about us. It’s about our brands and the mindset of their audiences. None of our work looks the same, and we love that,” said Henrichs. “At any agency the work is a reflection of the culture, and we’re a culture that celebrates individuality and ingenuity.”

Another major factor in Colle McVoy’s selection as Agency of the Year is its recent B Corp Certification, marking a commitment to creating positive social and environmental change. The rigorous process included numerous policy and program changes.

“We have always believed in using business as a force for good,” said Fruechte. “We see our B Corp Certification as a starting point for our future. It’s a commitment to our people, our culture and our clients that we will work to be even better tomorrow than we are today.”

Colle McVoy is part of Stagwell and its Constellation network.

About Colle McVoy
Colle McVoy, Adweek’s 2023 Midsize Agency of the Year, is a full-service creative agency that builds enduring relationships between forward-thinking brands and people. A Certified B Corp backed by an award-winning culture, Colle McVoy applies boundless creativity in times of rapid change to question the status quo, invent new methods and blaze paths to unchartered territories. Our client list includes some of the world’s most recognized brands, and our innovative culture has been named a Best Place to Work by Ad Age, Outside magazine and the Star Tribune. For more information, visit collemcvoy.com or follow us on LinkedIn, Instagram, Facebook and X (formerly Twitter).

About Stagwell
Stagwell (NASDAQ: STGW) is the challenger network built to transform marketing. We deliver scaled creative performance for the world’s most ambitious brands, connecting culture-moving creativity with leading-edge technology to harmonize the art and science of marketing. Led by entrepreneurs, our 13,000+ specialists in 34+ countries are unified under a single purpose: to drive effectiveness and improve business results for their clients. Join us at stagwellglobal.com.

CONTACT: 
Sarah Arvizo
pr@stagwellglobal.com

The findings show a significant communication gap between patients and their caregivers and providers about the array of physical and mental burdens of the disease. Over half of patients (51%) at least once a week hide their symptoms from others and as many as 68% avoid telling their friends for worry of being treated differently. The emotional weight of hemophilia is having a mental impact as well with 59% of patients feeling anxiety at least once a week and three quarters (75%) of hematologists reporting that their patients often feel depressed about their hemophilia.

The research also uncovered a troubling disconnect between patients’ overwhelming desire to play a more active role in the course of their treatment (83%) and those who feel their providers adequately include them in the process. Only 35% of patients surveyed globally believed that their healthcare provider involved them in discussions regarding their treatment and considers their concerns when it comes to treatment while 84 percent wish for more treatment options.

GLOBAL AND GENERATIONAL DISTINCTIONS
The research also uncovered some surprising differences across countries regarding the ages at which hemophilia patients receive care, ease of emotional impact discussions, and sentiments related to hiding symptoms.

• In the United States, the vast majority of caregivers (91%) cared for their child, of which most (94%) were under the age of 18. Only one percent were caring for an adult child (age 25-34).
• In Japan, by stark contrast, only three percent of caregivers cared for a child – among whom 67% care for a child under the age of 18.
• In China, almost all (98%) healthcare providers wish it was easier to discuss the emotional impact of living with hemophilia with their patients, while in the United States that sentiment drops down to 78%.
• Attitudes in Europe are much different than in the U.S. about avoiding telling friends about the disease for worry of being treated differently. In Europe, 80% of German respondents and 74% of UK respondents feel the need to hide their disease while only 41% of American respondents express the same concern.

The results of the survey provide valuable insights for caregivers, patients living with hemophilia, healthcare professionals, policymakers, and patient organizations worldwide. The goal is for results to drive action and dialogue that ultimately leads to new, innovative solutions to improve care for people living with hemophilia.

“As a company deeply committed to the global hemophilia community, Sanofi wanted to listen to the voices of people from around the world who are impacted by this disease at various stages of their life, to better understand their needs,” said Alaa Hamed, MD, MPH, MBA, Global Head of Medical Affairs, Rare Diseases and Rare Blood Disorders at Sanofi. “Our mission is to advance a model of care that provides the right support at the right time to serve this community so that people with hemophilia can focus less on living with this disease, and more on living the lives they choose.”

Full survey details, including methodology, audience demographics, global survey results, and more:  https://bit.ly/3ZGeiJC

Methodology for Hemophilia Life Stages and Changes Global Survey
The research was conducted online in the United States, United Kingdom, Germany, France, Italy, Spain, Japan, India, Canada, Australia, and China by The Harris Poll on behalf of Sanofi among 679 HCPs (health care providers whose primary medical specialty is hematology and see/treat 2+ patients with hemophilia per month), 950 patients (adults 18+ diagnosed with hemophilia), and 1,080 caregivers (adults 18+ who provide care or support to a friend or family member with hemophilia). The survey was conducted February 27 – April 10, 2023. 

Raw data were not weighted to adjust for geodemographics, except to provide each country equal share of voice, so thus are therefore only representative of the individuals who completed the survey. Respondents for this survey were selected from among those who have agreed to participate in our surveys.

The sampling precision of Harris online polls is measured by using a Bayesian credible interval. For this study, the sample data is accurate to within + 4.7 percentage points for HCPs, + 3.3 percentage points for patients, and + 3.0 percentage points for caregivers using a 95% confidence level. This credible interval will be wider among subsets of the surveyed populations of interest.   

All sample surveys and polls, whether or not they use probability sampling, are subject to other multiple sources of error which are most often not possible to quantify or estimate, including, but not limited to coverage error, error associated with nonresponse, error associated with question wording and response options, and post-survey weighting and adjustments. Responses may not add up to 100% due to weighting, computer rounding and/or the acceptance of multiple responses.

About The Harris Poll
The Harris Poll is a global consulting and market research firm that strives to reveal the authentic values of modern society to inspire leaders to create a better tomorrow. It works with clients in three primary areas: building twenty-first-century corporate reputation, crafting brand strategy and performance tracking, and earning organic media through public relations research. One of the longest-running surveys in the U.S., The Harris Poll has tracked public opinion, motivations and social sentiment since 1963, and is now part of Stagwell, the challenger holding company built to transform marketing.

About Stagwell
Stagwell (NASDAQ: STGW) is the challenger network built to transform marketing. We deliver scaled creative performance for the world’s most ambitious brands, connecting culture-moving creativity with leading-edge technology to harmonize the art and science of marketing. Led by entrepreneurs, our 13,000+ specialists in 34+ countries are unified under a single purpose: to drive effectiveness and improve business results for their clients. Join us at www.stagwellglobal.com.

About Sanofi
We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions. Sanofi is listed on EURONEXT: SAN andNASDAQ: SNY. Learn more at www.sanofi.com.

About Hemophilia
Hemophilia is a rare, lifelong condition in which the ability of a person’s blood to clot properly is impaired, leading to excessive bleeds and/or spontaneous bleeds into joints, muscles, and soft tissues that can result in joint damage, and chronic pain, and potentially impact quality of life. The severity of hemophilia is determined by the level of clotting factor activity in a person’s blood, and there is a negative correlation between risk of bleeding and factor activity levels. Globally, over 1 million people are estimated to have hemophiliaⁱ, divided over the different types, and sustainable access to diagnosis and treatment remains a challenge for a large number of these patients.

CONTACT:
Sarah Arvizo
pr@stagwellglobal.com

REFERENCES
ⁱ https://wfh.org